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Introduction
In recent years novel autoantibody-related neurological disorders have been recognized and studied with growing interest [1] [2] [3] [4] [5] . Early identification of clinical features, reliable methods of diagnosis, and prompt immunotherapy can lead to a favorable outcome in such acute/subacute neurological conditions, which may be associated with significant morbidity and mortality if left untreated [6, 7] .
In this context, autoimmune limbic encephalitis (LE), a rare and potentially treatable condition, is, unfortunately, often misdiagnosed [8] [9] [10] [11] . Although it was commonly considered of paraneoplastic origin [3, 12, 13] , the recent identification of antibodies (Abs) directed against neuronal surface antigens (NSAbs) contributed to reveal that a substantial proportion of cases LE is not associated with any malignancy [7, 14] . Different Abs targeting extracellular epitopes of cell surface receptors and trans-synaptic protein complexes are recognized to be responsible for specific encephalitis subtypes [14] [15] [16] .
LE is typically characterized by subacute amnestic syndrome, usually evolving over weeks to months, focal seizures and psychiatric features. Epileptic seizures, whose semiology generally
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suggests the involvement of temporo-mesial structures, are commonly considered as a cardinal symptom at disease onset. The immune-mediated mechanisms underlying epileptic phenomena in LE could not only induce ictogenesis during the acute phase of the disease, but also contribute to the long-standing epileptogenic process that leads to the development of chronic epilepsy. Seizures usually show a good response to immunotherapy even though, in a proportion of cases, they can persist over time [7, 10, 14, 17] . In this scenario, seizure recurrence might be either the expression of an enduring inflammatory insult, poorly responsive to therapy, or, alternatively, the manifestation of a chronic epileptic disorder. Factors predisposing to the development of chronic epilepsy have not been fully identified, given the complexity of LE pathogenesis and its phenotypical spectrum [14, [18] [19] [20] [21] [22] [23] .
The aim of this retrospective study, including a series of 33 consecutive LE patients, was to define the factors predisposing to the development of chronic focal epilepsy through the analysis of electro-clinical, laboratory and neuroimaging findings.
Patients and methods
Our retrospective study included a cohort of 33 consecutive adult patients, referred to the Department of Neurosciences and Mental Health ("Sapienza" University of Rome, Italy) and to the Complete demographic and clinical data are summarized in Table 1 . 
Statistical analysis
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Statistical analyses were carried out using SPSS for Mac, version 20.0 (IBM Corporation, Armonk, NY, USA). Results were considered significant at p<0.05.
Results
General clinical data, neuroimaging and laboratory findings.
A In 31 (94%) patients brain MRI at onset showed alterations involving mesial temporal lobes: they were bilateral in 22 out of 31 (71%), and in twelve cases they evolved to atrophy at 6-12-month follow-up. Hyponatremia (< 135mmol/L) was documented in 7 (21,2%) patients. Abs were detected in serum/CSF of 12 (36,3%) subjects: specifically, 7 had Abs anti-VGKC (LGI-1 in 3, CASPR-2 in 4), 2 showed Abs anti-NMDAR, whereas Abs anti-SOX-1, Ri/Hu and GAD65 were detected in one subject each.
Epileptological data and electro-clinical findings
Focal seizures represented the main clinical presentation of LE in all patients: focal impaired awareness seizures in 23 (69.7%) cases and focal aware seizures in 10 (30.3%) ; secondary generalized seizures were reported in 12 cases (36.3%), FBDS in 2 subjects (6%). Seizures were Table 2 .
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Therapeutic approach and seizure/epilepsy outcome
All patients received immunotherapy in the course of the disease: 19 out of 33 subjects were administered intravenous or oral steroids alone, whereas in 12 cases steroids were combined with intravenous immunoglobulin (IVIg) and in 4 with plasma exchange (PE) and IVIg. Two patients also received chronic treatment with azathioprine.
With regard to general clinical outcome, at last observation 20 (60.6%) patients did not report seizures, while the remaining 13 (39.4%) subjects had persistent seizures/epilepsy. Statistical analysis showed a significant association between unfavorable seizure outcome (defined as persisting seizures and development of chronic epilepsy) and delay in diagnosis (p=0.009), low seizure frequency at onset (p=0.02) and absence of amnestic syndrome (p=0.02); absence/rarity of inter-ictal epileptic discharges on EEG appeared to be associated with unfavorable outcome even if this finding did not reach statistical significance (p=0.06) ( Table 3) . No significant differences in terms of seizure/epilepsy outcome were observed between "seronegative" and "seropositive" patients; similarly no difference was detected by comparing patients treated with steroids alone and those treated with a combination therapy (steroids + IVIg or PE). Although a bilateral involvement of mesial temporal structures was associated with a worse outcome in terms of cognitive and psychiatric sequelae, it did not seem to influence seizure/epilepsy outcome.
As far as psycho-cognitive aspects are concerned, at follow-up memory deficits and psychiatric disturbances were observed in 12 (36,4%) and 14 (42,4%) cases, respectively.
Discussion
Over the last ten years, identification of autoimmune forms of encephalitis related to antibodies directed against neuronal surface or intracellular antigens have shown that CNS disorders can be ACCEPTED MANUSCRIPT
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antibody-mediated and benefit from immunomodulatory therapies. In particular, it has become increasingly clear that in case of epilepsy related to autoimmune process, conventional anticonvulsants cannot control seizures, and immunotherapy can represent both etiological and symptomatic treatment [1] [2] [3] [4] [5] [6] [7] .
Until today, in spite of the expanding knowledge of these conditions, some crucial aspects have not been fully elucidated. First of all, in clinical practice the definition of disease stage and prognosis might be challenging, especially in those cases in which immunotherapy does not allow complete recovery [24] . Indeed, in a significant proportion of patients, persisting seizures and/or psychocognitive symptoms can be observed, and it is often difficult to establish whether such clinical manifestations are the expression of an active immune-mediated process or represent long-term sequelae of an "extinguished" condition. As regards seizures, an inflammatory disease usually determines an initial tissue damage, which might be followed, in some cases, by an epileptogenic process leading to the development of chronic epilepsy. Indeed, it is not rare that temporal lobe seizures recur even if all clinical and instrumental (neuroimaging and laboratory) data suggest a complete resolution of the acute/subacute phase [8, 9, 25, 26] .
However, early factors predisposing to chronic epilepsy have not been specifically identified so far.
Despite the methodological limitations of our study, some data appear noteworthy, the most important being that patients with low seizure frequency at disease onset, absence of defined amnestic syndrome as well as absence/paucity of IED on EEG recordings showed an unfavorable seizure outcome and developed chronic, often drug-resistant epilepsy. It might be argued that an insidious clinical picture could hamper diagnosis, leading to a therapeutic delay, which is likely to negatively affect clinical course. In support of this hypothesis, we found that those patients with a "definite" limbic syndrome and more severe disease presentation showed better seizure outcome.
Indeed, the early recognition of a potentially reversible condition, such as LE, is always crucial for appropriate targeted treatment, and it is associated with better clinical outcome [24, 27, 28] .
As regards the other clinical and diagnostic (neuroimaging and laboratory) features, traditionally
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In line with the results obtained in our study, from an operative point of view, it could be wise to maintain a high level of neurological surveillance in case of subacute onset of temporal lobe seizures, especially in the elderly, even if other crucial clinical or laboratory markers of LEincluding cognitive impairment, psychiatric disturbances or Abs detection -are lacking.
Indeed, although recent attempts of providing clinical scores and scales could facilitate an early recognition [10, 26, 29] , in clinical practice a diagnostic delay is frequently observed, particularly in those conditions with subtle clinical presentation at onset [26, 30] .
In spite of some interesting suggestions, this study appears to be limited by several factors including its retrospective nature, the small sample size and the heterogeneity of the enrolled cohort in terms of time at first observation, anatomical damage documented by MRI, Abs profile, therapeutic schemes and psycho-cognitive evaluations. Considering these limitations, our preliminary results cannot allow us to draw any definitive conclusions, and longitudinal studies on larger samples are still warranted.
In conclusion, our study seems to provide interesting data suggesting that the "mild" forms of LE may be more insidious if compared with "definite" and explosive conditions in terms of seizure/epilepsy outcome. This observation could be explained by the diagnostic delay induced by the atypical/mild clinical presentation at onset. Indeed, in such condition the consequent therapeutic delay likely facilitates an inflammation-mediated epileptogenic process leading to chronic epilepsy.
The final consideration is that subtle LE may be a pitfall in clinical practice, highlighting the need for a better knowledge of the clinical spectrum of these not so rare entities.
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